DAVID G MENTER to Antineoplastic Agents
This is a "connection" page, showing publications DAVID G MENTER has written about Antineoplastic Agents.
Connection Strength
0.164
-
Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs. 2002 Dec; 11(12):1749-64.
Score: 0.043
-
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130.
Score: 0.037
-
?-Tocotrienol induces growth arrest through a novel pathway with TGF?2 in prostate cancer. Free Radic Biol Med. 2011 May 15; 50(10):1344-54.
Score: 0.019
-
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
Score: 0.018
-
Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther. 2009 Aug; 8(8):2319-28.
Score: 0.017
-
Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999 Jan 01; 59(1):14-8.
Score: 0.008
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
Score: 0.007
-
ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell. 2015 Aug 10; 28(2):183-97.
Score: 0.007
-
Transglutaminase stabilizes melanoma adhesion under laminar flow. Cell Biophys. 1991 Apr; 18(2):123-43.
Score: 0.005
-
Possible strategies for antimetastastic therapy. Prog Clin Biol Res. 1986; 212:217-49.
Score: 0.003